Asepsis announces the launch of Colistimethate Sodium for Injection in South Korea.
Asepsis announces the launch of Colistimethate Sodium for Injection in South Korea. This is Asepsis first product launch in South Korea. Asepsis has plans for a product line extension in the near future. Colistimethate sodium is used to treat Pseudomonas aeruginosa infections in cystic fibrosis patients, however has recently been indicated and received worldwide notice for use in treating multidrug-resistant infection and is one of the last-resort antibiotics for multidrug-resistant Pseudomonas aeruginosa, Acinetobacter and New Delhi metallo-β-lactamase multidrug-resistant Enterobacteriaceae, also known as the New Deli Superbug.
